CURRICULUM VITAE - GEORGE PETRIKKOS
Name:
George Petrikkos
Address:
1 Rimini Street, 124 62, Athens, Greece
Tel:
+30 210-5831989
Fax:
+30 210-5326426
E-mail:
petrikos@hol.gr
Graduate Studies
1966-1973: National and Kapodistrian University of Athens School of Medicine (M.D.)
Postgraduate Studies
1974-1977: Intern and Resident in Internal Medicine, “Laikon” General Hospital, Athens,
Greece
1978-1980: Scientific collaborator and research fellow, Infectious Diseases and Antimicrobial
Chemotherapy Research Lab “GK DAIKOS”, 1st Dept Propaedeutic Medicine , National and
Kapodistrian University of Athens Medical School, Athens, Greece
1979: PhD Thesis, National and Kapodistrian University of Athens Medical School, Athens
Greece
1979: Specialty National Boards in Internal Medicine
1985: Research fellow, St. Thomas’ Hospital Medical School, United Medical and Dental
Schools of Guy`s and St. Thomas’ Hospitals (University of London)
1986: Infectious diseases training, Ιnstitut Jules Bordet , Universite Libre De Bruxelles
1990: Training in molecular mechanism of resistance - Schering-Plough, New Jersey, USA
1999: Subspecialty in Infectious Diseases.
Appointments
1978-1979: Internal Medicine specialist in “Laikon” General Hospital ICU
1980-1982: Attending physician, “Laikon” General Hospital
1982-1984: Instructor in Internal Medicine, “Laikon” General Hospital, National and
Kapodistrian University of Athens Medical School, Athens, Greece
1986-1989: Lecturer in Internal Medicine and Infectious Diseases, “Laikon” General Hospital,
University of Athens Medical School, Athens, Greece
1989-2001: Assistant professor in Internal Medicine and Infectious Diseases, “Laikon” General
Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
1999-2009: Head of the Infectious Diseases and Antimicrobial Chemotherapy Research Lab
“GK DAIKOS”, 1st Dept Propaedeutic Medicine , National and Kapodistrian University of
Athens Medical School.
2001-2008: Associate Professor in Internal Medicine and Infectious Diseases, “Laikon” General
Hospital, National and Kapodistrian University of Athens, Athens, Greece
2008-2009: Professor in Internal Medicine and Infectious Diseases, “Laikon” General Hospital,
National and Kapodistrian University of Athens, Athens, Greece
2009- Present: Head of the 4th Dept Internal Medicine “ATTIKON’’ University Hospital,
Athens , Greece
2010-Present: Medical Director of ‘’ATTIKON’’ University Hospital, Athens, Greece.
Research interests
Dr Petrikkos clinical and research interests include: in vitro testing of the susceptibilities of nosocomial
and community-acquired bacteria to new antimicrobial agents; in vivo controlled clinical trials on the
efficacy and pharmacokinetics of newer antimicrobials; nephrotoxicity studies of antibiotics; neutropenic
host studies; fungal infections and antifungal agents; infectious diseases and resistance surveillance
studies; investigation of underlying resistance mechanism in microorganisms and surveillance studies on
antibiotic policies in Greek hospitals.
Memberships
President of the Mediterranean Society of Chemotherapy (MSC), the Cyprus Society of
Chemotherapy and Infectious Diseases
Past president of the Hellenic Society of Medical Mycology , and the Hellenic Society of
Lymphology.
Past Secretary General of the European Confederation of Medical Mycology (ECMM).
and the Hellenic Society of Chemotherapy
Member of the executive committee of the International Society of Chemotherapy ,the
Federation of European Societies of Chemotherapy and Infection (FESCI), the European Society
of Chemotherapy and the Hellenic Society of Infectious Diseases.
Coordinator of the ECMM/ISHAM Working Group on Zygomycosis and the ISC Working
Group on Fungal Infections .
Coordinator of the Working group of the Hellenic Society of Chemotherapy of the Febrile
Neutropenia.
Coordinator for the syntax guidelines for the Zygomycosis.
Member of the European Organisation for Research and Treatment of Cancer—Infectious
Diseases Group (EORTC-IDG), the European Conference on Infection in Leukemia and the
EFISG of ESCMID.
As a strong believer in evidence-base medicine Professor Petrikkos participated in tree European
guideline groups (ECIL ,ECMM/ISHAM, and EFISG – ESCMID) that have produced
guidelines on the diagnosis and treatment of infections in Leukemia patients, Zygomycosis –
Mucormycosis and Candidiasis
National (Cyprus) representative of European Union of Medical Specialist, section Infectious
Diseases (UEMM)..
Reviewer of 15 medical Journals and 12 congreses..
Dr. Petrikkos is the author of over 250 publications in Greek and international scientific journals
Recent Publications (Last 5 years)
1. Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M,
Stefanou I, Avlami A, Katsilambros N. Enterobacteriaceae bloodstream infections: presence of
integrons, risk factors, and outcome. Antimicrob Agents Chemother. 2007 Jul;51(7):2366-72.
2. Petrikkos G, Makrilakis K, Pappas S. Affirm VP III in the detection and identification of
Candida species in vaginitis. Int J Gynaecol Obstet. 2007 Jan;96(1):39-40.
3. Petrikkos G, Markogiannakis A, Papaparaskevas J, Daikos GL, Stefanakos G, Zissis NP,
Avlamis A. Differences in the changes in resistance patterns to third-and fourth-generation
cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli
clinical isolates following a restriction policy in a Greek tertiary care hospital. Int J Antimicrob
Agents. 2007 Jan;29(1):34-8.
4. G.Petrikkos,A.Skiada. Recent advances in antifungal chemotherapy.Int J Antimicrob
Agents 2007;30:108-17.
5. Petrikkos GL, Hadjisoteriou M, Daikos GL. PCR versus culture in the detection
of vaginal Ureaplasma urealyticum and Mycoplasma hominis. Int J Gynaecol Obstet.
2007 Jun;97(3):202-3. Epub 2007 Mar 21. PubMed PMID: 17368648.
6.Epidemiological and Clinical investigation of Gram-negative anaerobic infections in Greece.
A.Katsandri,A.Avlamis,NJ
Legakis,G.L.Petrikkos,A.Pantazatou,J.Papaparaskevas.International Journal of Antimicrobial
Agents 2007;29:379-379.
7. Pappas S, Makrilakis K, Anyfantis I, Mitroussia-Ziouva A, Hadjisoteriou M, Petrikkos G.
Clinical evaluation of affirm VP III in the detection and identification of bacterial vaginosis. J
Chemother. 2008 Dec;20(6):764-5.
8. Zappas S, Giakoupi P, Vourli S, Hatjichristodoulou Ch, Polemis M, Tzouvelekis L S, Avlami
A, Daikos G L, Petrikkos G. Epidemiology of metalloenzyme producing P. aeruginosa in a
tertiary hospital in Greece. Journal of Chemotherapy. 2008;20:307-11
9.Epidemiology of metalloenzyme producing P.aeruginosa in a tertiary hospital in
Greece.Zappas S,Giakoup P,Vourli S,Hatzjichristodoulou Ch,Polemis M,Tzouvelekis
LS,Avlami A,Daikos GL,Petrikkos G. Journal of Chemotherapy.2008;20:307-11.
10.Risk factors for coexistence of fluoroquinolone resistance and ESBL production among
Enterobacteriaceae in a Greek university hospital.
A.Katsandri,A.Avlamis,A.Vasilakopoulou,V.Mela,C.Kosmidis,J.Papaparaskevas and
G.L.Petrikkos. Journal of Chemotherapy 2008;20:452-7.
11. G.L.Daikos, P.Petrikkos, M.Psichogiou, C.Kosmidis, E.Vryonis, A.Skoutelis, K.Georgousi,
G. Petrikkos. Prospective observational study of the impact of VIM-1 metallo-β- lactamase on
the outcome of patients with Kebsiella pneumoniae bloodstream infections. Antimicrobial
Agents and Chemotherapy 2009;53: 1868-1873
12. Vasilakopoulou A, Psichogiou M, Tzouvelekis L, Tassios PT, Kosmidis C, Petrikkos G,
Roma ES, Charvalos E, Passiotou M, Avlami A, Daikos GL. Prevalence and characterization of
class 1 integrons in Escherichia coli of poultry and human origin. Foodborne Pathog Dis. 2009
Dec;6(10):1211-8.
13. Petrikkos GL. Lipid formulations of amphotericin B as first –line treatment of
zygomyucosis. Clin Microbiol Infect 2009;15(5):87-92.
14.Prealbumin’ s Assessment in Hemodialysis and Renal Transplant
Patients.S.Chrysostomou,Ch.Stathakis,G.Petrikkos,G.Daikos,A.Gompou,D.Perrea.Journal of
Renal Nutrition 2009.
15. Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect. 2009;15(5):41-5.
16. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P, Tzanetou K,
Markogiannakis A, Thomopoulos G, Vafiadi I, Petrikkos G. Serum bactericidal activity of
three different dosing regiments of colistin with implications for optimum clinical use. J.
Chemother 2010;22(3):175-8.
17. Van de Mortel TF, Apostolopoulou E, Petrikkos G. A comparison of the hand hygiene
knowledge, beliefs, and practices of Greek nursing and medical students. Am J Infect Control
2010;38(1):75-7.
18. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E,
Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL,
Roilides E, Mitrousia-Ziouva A, Petrikkos G for the European Confederation of Medical
Mycology Working Group on Zygomycosis. Zygomycosis in Europe: Analysis of 230 cases
accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working
Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect2011.
19. Panagea T, Galani I, Souli M, Karantani I, Giamarellou H, Petrikkos G.Int J Antimicrob
Agents. 2011 Nov;38(5):451-2. Epub 2011 Aug 15. Glycopeptide and daptomycin susceptibility
and vancomycin heteroresistance of methicillin-resistant Staphylococcus aureus (MRSA) clinical
isolates from a Greek university hospital.
20. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Clin Infect
Dis. 2012 Feb;54 Suppl 1:S23-34. Review. Epidemiology and clinical manifestations of
mucormycosis.
21. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, Kontoyiannis
DP, Walsh TJ.Clin Infect Dis. 2012 Feb;54 Suppl 1:S73-8. Combination therapy for
mucormycosis: why, what, and how?
22. Kontoyiannis DP, Lewis RE, Lortholary O, Spellberg B, Petrikkos G, Roillides E, Ibrahim
A, Walsh TJ. Clin Infect Dis. 2012 Feb;54 Suppl 1:S79-85. Erratum in: Clin Infect Dis. 2012
Apr;54(8):1220. Future directions in mucormycosis research.
23. Tsiodras S, Drogari-Apiranthitou M, Pilichos K, Leventakos K, Kelesidis T, Buitrago MJ,
Petrikkos G, Panayiotides I.Am J Trop Med Hyg. 2012 Feb;86(2):261-3. Review. An unusual
cutaneous tumor: African histoplasmosis following mudbaths: case report and review.
24. Collaborators (1290). HIV-CAUSAL Collaboration.Clin Infect Dis. 2012 May;54(9):136472. Epub 2012 Mar 28. Impact of antiretroviral therapy on tuberculosis incidence among HIVpositive patients in high-income countries.
25. Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni
G, Mitroussia-Ziouva A, Tsakris A, Petrikkos G.J Antimicrob Chemother. 2012 Apr 25. In vitro
antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of
amphotericin B, posaconazole and anidulafungin in pairs.
26. Papadopoulos A, Pantazis N, Panagopoulos P, Kourkounti S, Xylomenos G, Chini M,
Petrikkos G, Sambatakou H, Ioannidou P, Kordosis T, Panos G, Touloumi G.J Chemother.
2012;24(1):38-47. Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals.
27. Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M.J
Antimicrob Chemother. 2012 Jun 4. Mecillinam/clavulanate combination: a possible option for
the treatment of community-acquired uncomplicated urinary tract infections caused by extendedspectrum β-lactamase-producing Escherichia coli.